The use of nabilone for the treatment of pain in a tertiary chronic pain centre
Lori Montgomery, Nicole Labrie, John Fralick, Tyler Williamson, Meghan Doraty, Helen Tam, David Linton, Neil Drummond
Marta Shaw at firstname.lastname@example.org, 403.210.9259
Nabilone, a synthetic cannabinoid, is approved for use in Canada for the treatment of chemotherapy-induced nausea and vomiting. However, little is known regarding the frequency and efficacy of nabilone prescription in practice, or the specific pain conditions for which it is prescribed.
The objective of this paper is to describe the off-label use of nabilone for the treatment of chronic pain in a routine clinical practice setting.
Data from 250 patient charts at a tertiary pain centre in Calgary, Alberta, Canada, were collected, including demographic information, pain history, treatment information, and change in pain score. Time to nabilone discontinuation is described using Kaplan-Meier survival curves.